Spenser Lin No Comments

Healthcare News, Deals, and Investments Update October 26th, 2026

Healthcare News and Deals

  1. EQT Private Equity has agreed to acquire QIAGEN N.V. (NYSE: QGEN) in a recommended all-cash voluntary public takeover offer valuing the molecular testing company at approximately $12.1 billion enterprise value. EQT XI, through Crown NL Bidco, is offering €46.50 per share in cash — a 40.3% premium to the unaffected XETRA close on July 8. Including about $1.1 billion of net debt, the deal values QIAGEN at roughly $12.1 billion. The Dutch tools and diagnostics company has been the subject of takeover talk for years. Both boards are recommending the offer after a strategic review. Affiliates of the Abu Dhabi Investment Authority and Canada Pension Plan Investment Board are co-investing. QIAGEN will keep its name and brand. (Link)
  2. HealthSpan Partners to Acquire Surgery Partners, Establishing a Leading Outpatient Surgical Care Platform HealthSpan Partners has agreed to buy Surgery Partners (NASDAQ: SGRY), the Bain Capital-backed operator of ambulatory surgery centers and surgical hospitals. Reports put the value at about $6 billion, including roughly $3.5 billion of debt, with Bain keeping its nearly 40% stake. Surgery Partners runs more than 170 surgical facilities across 30 states. HealthSpan is an affiliate of Bon Secours Mercy Health and is picking up a large outpatient surgical footprint. (Link)
  3. AEA Investors-Backed American Oncology Network Agrees to a $2.4 Billion Sale to Cencora, Adding 350+ Community Oncology Providers to Cencora’s Physician MSO Platform. Cencora (NYSE: COR) signed a definitive agreement on October 20 to buy the roughly 96% of Fort Myers-based American Oncology Network (OTCQX: AONC) it does not already own. The deal values AON at $2.4 billion enterprise value — $2.3 billion at closing plus up to $100 million in contingent value rights. Some AON holders can roll up to 25% of their equity; if they do, Cencora expects to write a check of about $1.7 billion for 75% ownership. AON brings more than 350 providers across 21 states and adds 12 new states to Cencora’s MSO footprint. Clinical decisions stay with AON physicians. It is Cencora’s fourth physician-platform deal since January 2025, after Retina Consultants of America, OneOncology and the EyeSouth retina business. (Link)
  4. Kohlberg Is Buying Alcanza Clinical Research from Martis Capital for Approximately $800–850 Million Axios Pro reported that Kohlberg is buying Alcanza Clinical Research from Martis Capital for between $800 million and $850 million. Alcanza is a clinical research site network founded in 2021 that focuses on inclusive trial access and runs more than 25 sites across the U.S. and Puerto Rico. It does Phase I–IV studies for pharma sponsors and CROs. (Link)
  5. Blackstone- and TPG-Backed Hologic Signs a Definitive Agreement to Acquire Reveal Genomics, Maker of the HER2DX Breast Cancer Test Hologic, now owned by Blackstone and TPG after a take-private of up to about $18.3 billion, has agreed to buy Barcelona-based Reveal Genomics. Reveal makes the HER2DX genomic test, which helps guide therapy for HER2-positive breast cancer. The test sits alongside Hologic’s Breast Cancer Index assay and adds another treatment-selection tool. It is the first clear sign that the new owners plan to use Hologic as a buy-and-build platform in women’s-health diagnostics. (Link)
  6. Apogem Capital Leads a Minority Investment in Revelstoke-Backed Family Care Center, Returning Capital to LPs While Revelstoke Stays In Family Care Center, the outpatient mental health platform backed by Revelstoke Capital Partners, closed a minority equity sale led by Apogem Capital. Revelstoke is staying in. Since Revelstoke partnered with founder Dr. Chuck Weber in December 2020, the company has grown entirely by opening new clinics — from four locations in one state to more than 50 across five states. It now has more than 800 providers and expects nearly 1 million treatment sessions in 2026, across therapy, psychiatry, TMS and intensive outpatient programs. Revelstoke described the deal as a way to return capital to its LPs without selling the whole company. Jefferies advised Family Care Center. (Link)
  7. EQT-Backed Sagility Agrees to Acquire Tennessee’s Chirok Health for Up to $32.35 Million, Adding Clinical Documentation Integrity and Coding Capability Sagility (US) Holdings, a subsidiary of the EQT-backed healthcare BPO Sagility, signed a definitive agreement on October 21 to buy Chirok Health, a Tennessee firm that does revenue cycle management, clinical documentation integrity and medical coding. The price is $20 million at closing plus up to $12.35 million in earnout. Chirok did about $9 million of revenue in 2025. The deal adds provider-side capability for Sagility. (Link)
  8. Altaris-Backed Tegria Acquires CloudWave, Its First Add-On Since the Providence Carve-Out, to Build a Healthcare Cybersecurity and Hosting Platform Tegria, the healthcare consulting, managed services and technology company that Altaris carved out of Providence in January 2026, bought CloudWave. CloudWave does cloud hosting, managed IT and cybersecurity (LECO sold BlueOrange to Cloudwave in 2025) only for healthcare clients, and it runs a dedicated 24/7 security operations center. CloudWave CEO Erik Littlejohn becomes president of Tegria’s Enterprise Technical Solutions. It is Tegria’s first add-on since the carve-out. (Link)
  9. Renovus Capital Partners Strikes a Deal for Chicagoland Orthopedic Home Health Provider Aspire Home Health Care Renovus Capital Partners, the Philadelphia-area lower-middle-market firm that already owns Louisiana home health and hospice platform Superior Health Holdings, has agreed to buy Aspire Home Health Care. Aspire was founded in 2013 and is based in Morton Grove, Illinois. It provides skilled nursing and therapy at home for patients recovering from orthopedic procedures, surgeries and complex conditions. The deal gives Renovus a post-surgical home health business in the Chicago market. (Link)
  10. Kohlberg-Backed Trinity Life Sciences Acquires Verix to Add AI-Driven Commercial Execution Tools for Pharma Trinity, the life sciences commercialization advisory and analytics firm that Kohlberg & Company has owned since 2021, bought Verix. Verix’s Tovana platform uses AI to give pharmacommercial teams next-best-action recommendations, patient finding and HCP targeting, and it is used by large pharma companies. The deal moves Trinity from strategy and insights into software that field teams actually use day to day. (Link)
  11. New Harbor Capital’s LGM Pharma Acquires New Jersey Contract Lab Sannova Analytical LGM Pharma, the API sourcing and CDMO platform that New Harbor Capital has majority-owned since 2017, bought Sannova Analytical. Sannova is a Somerset, New Jersey contract lab that does bioanalytical and CMC testing for pharma and biotech companies. It had been backed by SFW Capital Partners since 2022. The deal adds an East Coast testing operation to LGM’s development and manufacturing services. (Link)
  12. Blue Sea Capital-Backed One Physics Adds Two West Coast Medical Physics Firms, Expanding into the Pacific Northwest and Northern California One Physics, the largest outsourced medical physics company in North America, is buying two firms that do diagnostic medical physics and radiation safety work in the Pacific Northwest and Northern California. Blue Sea Capital has backed One Physics since 2019 and moved it into a single-asset continuation vehicle earlier this year. The company has already done 22 acquisitions and serves more than 7,000 client sites in 45+ states with over 210 physicists. (Link)
  13. HCAP Partners- and Salt Creek-Backed Real Diagnostics Adds Saliva-Based Oral Health Testing Firm SimplyTest Real Diagnostics (RealDx), the Maryland-based high-complexity molecular lab that Salt Creek Capital and HCAP Partners bought in September 2025, acquired SimplyTest. SimplyTest makes saliva-based tests, including its PERIO test, that identify bacteria linked to gum disease, and it sells to dentists and functional medicine practices. The add-on gives RealDx, which serves physician offices and clinics in 17 states, a cash-pay dental product line next to its reimbursed UTI, STI and respiratory testing. (Link)
  14. Thompson Street Capital-Backed Savillex Completes Carve-Out of Entegris’ Life Sciences Fluid Management Business Savillex, the Eden Prairie, Minnesota high-purity fluoropolymer and single-use bioprocessing company backed by Thompson Street Capital Partners, completed its acquisition of Entegris’ (Nasdaq: ENTG) life sciences fluid management business. The business includes Aramus and PE bioprocess bags, single-use assemblies and components. The carve-out deepens Savillex’s position with biopharma and cell and gene therapy manufacturers, and lets Entegris focus on semiconductor materials. It follows Savillex’s 2024 acquisition of Optimum Processing. Sidley advised Savillex. (Link)
  15. Sopris Capital Merges the Blackford Analysis Imaging-AI Platform, Carved Out of Bayer, into Portfolio Company Azra AI Azra AI said on October 20 that it had completed the acquisition of Blackford Analysis from Sopris Capital. Sopris had carved Blackford out of Bayer earlier in the month. Blackford’s vendor-neutral orchestration platform gives radiology departments access to more than 130 imaging-AI applications from 45+ vendors. Azra identifies patients with cancer and other complex conditions and coordinates their follow-up care. Putting the two together connects the imaging finding to the care pathway that follows it. (Link)
  16. Pacific Lake Partners-Backed Vitana Pediatric & Orthodontic Partners Acquires Louisiana’s Hollis Orthodontics, Its Fifth Deal of 2026 Vitana Pediatric & Orthodontic Partners, a dentist-led partnership organization backed by Pacific Lake Partners that focuses only on pediatric dental and orthodontic practices, bought Hollis Orthodontics in Prairieville, Louisiana, outside Baton Rouge. The practice is led by Dr. Bryan Hollis. Vitana now supports practices in Florida, Alabama, Louisiana, Pennsylvania and New Jersey. This is its fifth deal of 2026. (Link)
  17. DuneGlass Capital-Launched Aviva Aesthetics Enters Florida Through a Partnership with Allenby Cosmetic Dermatology Aviva Aesthetics, the founder-led medical aesthetics network that DuneGlass Capital launched, partnered with Allenby Cosmetic Dermatology, the practice of cosmetic dermatologist Dr. Janet Allenby. It is Aviva’s first Florida location, about seven weeks after the Perfect Skin Center partnership took the platform to 20 sites. Aviva markets its “Entrepreneur Equity” model to founders who have turned down traditional private equity MSO structures: founders keep decision-making authority and financial upside. (Link)
  18. Redesign Health and Sheba Medical Center’s ARC Global Merge in an Approximately $2 Billion Combination to Build an End-to-End Health System Innovation Platform Redesign Health, the venture and applied technology firm that has launched more than 60 healthcare companies, is merging with ARC Global, the innovation arm of Israel’s Sheba Medical Center. The combined company is valued at about $2 billion, according to a source familiar with the deal. The parties have also agreed to buy AVIA, the health-system digital technology advisory firm. Brett Shaheen will be CEO; Stephen Klasko, M.D., will chair the board; and ARC founder Eyal Zimlichman, M.D., will become vice chair. The idea is to put engineering, AI and capital inside health systems so clinician-originated ideas can become products and companies that scale across a network of more than 100 systems. (Link)
  19. Horizon Mutual Holdings, parent of Horizon Blue Cross Blue Shield of New Jersey, has entered an agreement to acquire Summit Health New Jersey, including its New Jersey CityMD urgent care centers, in a transaction reported at more than $1 billion. Horizon confirmed the agreement, which is subject to regulatory review and could close by year-end. Summit Health is one of New Jersey’s largest multispecialty physician networks; the New Jersey portion includes primary, specialty and 39 CityMD urgent care sites. It is Horizon’s largest deal since its 2022 conversion to a nonprofit mutual holding company. Horizon said the acquisition is meant to preserve access, improve quality and affordability for members, and support continued independence of Summit’s physicians. (Link)
  20. Alcon Acquires Rhode Island’s Neurotech Pharmaceuticals for $550 Million Plus Milestones, Picking Up ENCELTO, the Only FDA-Approved MacTel Type 2 Therapy Alcon completed the acquisition of Neurotech Pharmaceuticals on October 20 for $550 million upfront, plus possible contingent payments tied to commercial milestones. The deal brings in ENCELTO (revakinagene taroretcel-lwey), an encapsulated cell therapy implant approved in March 2025 and the only FDA-approved treatment for macular telangiectasia type 2. Neurotech estimates there are about 25,000 MacTel patients in the U.S., with 2,000 to 3,000 new diagnoses each year. Alcon expects the deal to modestly add to sales growth and slightly reduce core EPS in 2027, then add to EPS after that. (Link)
  21. Labcorp Agrees to Buy Myriad Genetics’ Prenatal Health Testing Business for $210 Million in Cash as Myriad Narrows Its Focus to Oncology Labcorp (NYSE: LH) signed a definitive agreement to buy Myriad Genetics’ (NASDAQ: MYGN) Prenatal Health testing business, including the Prequel, Foresight, SneakPeek and FirstGene tests, for $210 million in cash plus inventory value at closing. Labcorp expects about $160 million of first-year revenue, slight accretion to adjusted EPS in year one, and average diagnostics-segment margins by the end of year two. The carve-out comes out of Myriad’s strategic review, after prenatal revenue fell about 16% in the first half of 2026. It follows closely on Labcorp’s $722 million BioReference deal. (Link)
  22. Risant Health has signed a definitive agreement to acquire INTEGRIS Health, Oklahoma’s largest nonprofit health system, pending regulatory approvals. INTEGRIS Health would become Risant’s third member system after Geisinger and Cone Health. Headquartered in Oklahoma City, INTEGRIS operates roughly 20 acute and specialty hospitals and the state’s largest physician network, employing about 13,000 people. It will keep its name, medical staff, brand and leadership. Risant, backed by Kaiser Permanente, is focused on value-based care; INTEGRIS leadership pointed to access to additional capital, technology including Epic, and clinical tools that the system could not scale on its own. (Link)
  23. Bolt Biotherapeutics, Inc. (NASD: BOLT) has completed the acquisition of Prana Therapies, Inc. in a stock-for-stock reverse merger concurrent with a $120 million private placement. The sign-and-close reverse merger exchanges Prana equity for Bolt common stock and Series D non-voting convertible preferred stock. A concurrent financing raises $120 million in upfront gross proceeds from the purchase of Series D preferred, with up to an additional $60 million available if accompanying warrants are exercised. Investors include Deep Track Capital, ADAR1 Capital, Andreessen Horowitz, LYFE Capital, Eventide Asset Management, Casdin Capital and Soleus Capital. The combination focuses on Prana’s INSPIRE platform and lead bispecific antibody PRA-216 (IL-4Rα/TSLP). Proceeds are expected to fund operations into 2028. Sheila Gujrathi, M.D., former Prana CEO, joins as chief strategy officer and board member. (Link)
  24. OpenAI Acquires a16z-, 8VC- and Insight-Backed Orchestra Bio to Bring Agentic Drug-Program Management into Its Rosalind Life Sciences Suite OpenAI acquired San Francisco-based Orchestra Bio on October 20. Orchestra’s AI agents help biopharma teams coordinate drug development programs — they monitor studies, track timelines and flag delays that can spread across a program. Orchestra came out of stealth in 2025 with about $20 million from investors including Andreessen Horowitz, 8VC and Insight Partners. Its team and technology will be folded into Rosalind, OpenAI’s life sciences offering, which already has pharma partners such as Moderna and Novo Nordisk. (Link)
  25. Hackensack Meridian Health Signs a Definitive Agreement to Acquire Hunterdon Health, Committing $230 Million to the Central New Jersey System Hackensack Meridian Health, New Jersey’s largest health system, signed a definitive agreement to acquire Hunterdon Health. Hunterdon is anchored by the 184-bed Hunterdon Medical Center teaching hospital and has more than 30 medical practices. HMH committed $230 million in investment, and the deal would bring it to 19 hospitals. No closing timeline was given. (Link)
  26. Beacon Biosignals Acquires Snap Diagnostics to Expand EEG-Enabled Home Sleep Testing Nationwide Beacon Biosignals, an AI-powered precision neurotechnology company, has acquired Snap Diagnostics, a national home sleep testing provider. Snap operates as a Medicare-registered Independent Diagnostic Testing Facility accredited by The Joint Commission and serves patients in all 50 states with end-to-end shipping, scoring and interpretation. The acquisition more than doubles Beacon’s patient reach and gives it a channel to bring its FDA-cleared EEG headband technology into primary care, telehealth and specialty settings starting in 2027. (Link)
  27. CentraCare and Stellis Health Announce Plans to Integrate, with Completion Targeted for January 1, 2027 CentraCare, the integrated nonprofit health system serving Central, Southwest and West Central Minnesota, and Stellis Health, a physician-owned medical group with more than 60 providers in Wright County, have announced plans for Stellis to become part of CentraCare. The combination builds on a longstanding partnership that already includes a shared Epic electronic medical record and collaboration at CentraCare – Monticello. Stellis shareholders have voted to proceed. (Link)
  28. Further Acquires Welbi to Combine Senior Living Sales AI with Resident Experience Management Further, the Charleston-based AI platform for senior living sales and marketing, has acquired Ottawa-based Welbi, a resident experience platform. Together they reach more than 8,000 senior living communities. Further’s suite (ProspectAI, SalesAI, ResidentAI, OpsAI) helps operators attract and convert prospects; Welbi helps communities personalize daily programming and track engagement. Welbi founder and CEO Elizabeth Audette-Bourdeau will continue to lead Welbi’s operations. (Link)
  29. Vimian Group Expands Its Veterinary Surgical Offering Through the Acquisition of Norfolk Medical Products Vimian Group AB (publ), the Stockholm-based animal health company, has signed an agreement to buy Norfolk Medical Products, a family-owned U.S. provider of implants and consumables for veterinary soft-tissue surgery. Norfolk, founded in 1981, does about $6.9 million in revenue and specializes in vascular access ports and related implantable solutions. The deal is Vimian’s first move into specialized soft-tissue surgery and is expected to have a marginal impact on 2026 earnings. (Link)

Venture Deals and Other

  1. Star Therapeutics has raised $200 million in private financing to advance its preclinical pipeline of novel biologics after prior exits of subsidiary assets. The round was co-led by OrbiMed and Janus Henderson Investors, with participation from RA Capital Management, Sofinnova Investments and others. Star, founded by Adam Rosenthal, has a history of discovering biologics and advancing them through subsidiaries that were later sold or taken public, including the sale of Vega Therapeutics to Incyte and the IPO of Electra Therapeutics. Rosenthal called the financing a reset, with the company focusing on early-stage programs rather than a hub-and-spoke model going forward. Proceeds will be used to move current preclinical assets into the clinic. (Link)
  2. OpenAI Startup Fund and Founders Fund Co-Lead a $45 Million Round for Coherence Neuro’s AI-Enabled Brain Tumor Implant The round was co-led by OrbiMed and Janus Henderson Investors, with participation from RA Capital Management, Sofinnova Investments and others. Star, founded by Adam Rosenthal, has a history of discovering biologics and advancing them through subsidiaries that were later sold or taken public, including the sale of Vega Therapeutics to Incyte and the IPO of Electra Therapeutics. Rosenthal called the financing a reset, with the company focusing on early-stage programs rather than a hub-and-spoke model going forward. Proceeds will be used to move current preclinical assets into the clinic. (Link)
  3. FirstMark Capital Leads a $40 Million Series A for Baba, with CVS Health Ventures Joining, to Build AI Care Teams for Medicare and Medicaid Members New York-based Baba, an applied AI company working on the Medicare and Medicaid experience, raised a $40 million Series A led by FirstMark Capital. CVS Health Ventures and Valtruis joined, and General Catalyst, Genius Ventures and Ground Up Ventures returned. The funding will expand Baba’s clinical care teams, advance its AI research and grow its health plan partnerships. (Link)
  4. Healthleap has raised $38 million in seed and Series A funding to expand its AI platform that flags at-risk hospital patients from electronic medical records. The total comprises an $8 million seed round co-led by Sequoia Capital and First Round Capital and a $30 million Series A led by Hummingbird Ventures. Founded in 2022 by siblings Jemima and Josiah Meyer, the South African-origin company analyzes clinical notes, labs, vitals and medication records to surface risk scores for conditions such as malnutrition and delirium. It is used in more than 50 hospitals including Penn Medicine, Cedars-Sinai, Houston Methodist and Emory Healthcare. (Link)
  5. Allumia Ventures Leads a $10 Million Series A for Home-Based Lung Disease Telehealth Provider Kivo Health Kivo Health, a telehealth provider of virtual pulmonary rehabilitation and care for COPD and other chronic lung diseases, raised a $10 million Series A led by Allumia Ventures, according to Axios Pro. Home-based respiratory care is an area health plans and risk-bearing providers have been looking at for value-based contracts. (Link)
  6. Zai Lab Limited (NASD: ZLAB; HKEX: 9688) has entered a securities purchase agreement for a $250 million PIPE financing of American Depositary Shares. Zai Lab agreed to sell 11,340,000 ADSs at $22.04 each, for expected gross proceeds of about $250 million before fees. The financing is led by TCGX and includes participation from abrdn World Healthcare Fund, ADAR1 Capital Management, Balyasny Asset Management, Cormorant Asset Management, Frazier Life Sciences, RA Capital Management, RTW Investments, Wellington Management and others. Net proceeds are intended primarily to support continued global development of zocilurtatug pelitecan (zoci), the company’s DLL3-targeting antibody-drug conjugate. Leerink Partners is the exclusive placement agent. (Link)

IPOs:

  1. Lycia Therapeutics Prices Upsized $317.5 Million Initial Public Offering at $18 per Share Lycia Therapeutics, Inc. (NASD: LYCA), a clinical-stage biotechnology company developing LYTAC degraders of disease-causing extracellular proteins, priced its upsized IPO of 17,640,000 shares at $18.00 per share, for expected gross proceeds of about $317.5 million. The company had originally marketed 14.7 million shares at $16–$18. Lead programs include LCA-0061 (an IgE degrader for food allergy) and LCA-0321 (an autoantibody degrader for Graves’ disease). Jefferies, TD Cowen, Evercore ISI and Guggenheim Securities are joint book-running managers. The platform is based on work by Nobel laureate Carolyn Bertozzi. (Link)
  2. Anthropic Files Public S-1 for Nasdaq IPO Under Ticker (NASD:ANT) Anthropic, the AI lab behind the Claude model family, has filed a public S-1 registration statement with the SEC for an initial public offering on Nasdaq under the ticker ANT. The Claude maker is targeting a valuation of $1.5–2 trillion, which would make it one of the largest IPOs on record and roughly double the $965 billion mark from its May funding round. First-half 2026 revenue was $16.3 billion, against about $4.6 billion for all of 2025. Third-quarter revenue reached $16.8 billion, up about 45% sequentially, and the company said it was profitable on an adjusted basis. The $80.7 billion first-half net loss is largely a non-cash charge tied to the rising valuation. (Link)
Spenser Lin No Comments

Healthcare News, Deals, and Investments Update September 28th, 2026

Healthcare Weekly News and Deals – Sept 28th, 2026

  1. Webster Equity Partners to acquire Lifecore Biomedical (NASD: LFCR) for $6.28 per share in cash plus CVRs, valuing the sterile-injectable CDMO at up to $663.7 million. Lifecore is a Chaska, Minnesota contract manufacturer for sterile injectables — syringes, vials and cartridges, including complex formulations — and a large producer of injectable-grade hyaluronic acid. Common holders get $6.28 a share in cash, a 49.5 percent premium to the September 25 close. Contingent value rights tied to 2028 and 2029 revenue and 2030 EBITDA can add $160 million in the aggregate, or $9.67 a share if every milestone hits. MidCap Financial, MSD Partners and Alcon committed the debt; Webster committed the equity. The merger agreement includes a 30-day go-shop. The company stays in Chaska under the Lifecore name, with a close aimed at year-end. (Link)
  2. Ardan Equity is investing in clinical trial technology company Clinical ink alongside existing backer GI Partners at a total enterprise value of more than $500 million. Healthcare software specialist Ardan Equity is investing in Clinical ink, the clinical trial technology company, alongside existing backer GI Partners. GI Partners acquired a majority interest in Clinical ink in August 2020, when prior investor NovaQuest stayed on as a minority holder and management invested significantly. The new round adds a sponsor that invests exclusively in healthcare software, while GI Partners keeps its exposure as Clinical ink builds on a platform that brings data, technology and patient science together for trial sponsors. (Link)
  3. Clearlake Capital Group and Charlesbank Capital Partners have agreed to inject approximately $175 million of preferred equity into distressed healthcare software provider Symplr, as part of a creditor-backed recapitalization designed to shore up its finances and extend its debt maturities. Clearlake Capital Group and Charlesbank Capital Partners will provide around $175 million of preferred equity to Symplr under a restructuring agreed with several creditor groups, with the sponsors deferring interest on newly issued junior debt to preserve cash. Second-lien lenders are expected to add $103.5 million through a first-out second-lien loan, while first-lien holders would receive a 100-basis-point coupon increase for extending the 2027 maturity by three years. Symplr’s roughly $1.2 billion first-lien term loan was recently quoted near 71.4 cents on the dollar amid concerns over AI’s impact on software. Company is held in a single-asset continuation vehicle. (Link)
  4. Existing shareholders Star One Global Capital Limited and Eliyahou Harari have fully funded an $18 million registered direct offering in Nasdaq-listed capsule endoscopy developer CapsoVision (CV), buying 3,163,444 shares at $5.69 each. CapsoVision (CV) has raised about $18 million through a registered direct offering funded entirely by existing shareholders Star One Global Capital Limited and Eliyahou Harari. Under a September 17 securities purchase agreement, the investors agreed to buy 3,163,444 shares at $5.69, a roughly 5% discount to the prior Nasdaq close, with no underwriter involved. The insider-backed raise, approved by the board and reviewed by the audit committee, strengthens the balance sheet of the Saratoga, California-based capsule endoscopy developer, which has a market value of about $299.8 million. Proceeds will fund sales and marketing, R&D and working capital as it advances AI-assisted CapsoCam Plus and a second-generation colon capsule. (Link)
  5. Lexeo Therapeutics (NASD: LXEO) has agreed to acquire Mantle Therapeutics for $8.3 million in cash and equity plus up to $13 million in milestones, adding Friedreich ataxia programs. Mantle is a private clinical-stage company with four Friedreich ataxia candidates designed to raise or replace frataxin in the brain. One is an oral combination already in patients; another is an RNA construct linked to an anti-TfR1 antibody fragment. On the same day Lexeo signed a sponsored-research agreement with Weill Cornell on intra-cisternal dosing of LX2006 and took options from Vivet Therapeutics and Apertura Gene Therapy. Management says the cash on hand still lasts into 2028. The acquisition is expected to close this quarter. (Link)
  6. Avesi Partners has made an investment in St. Louis-based New Age Medical, a spinal MedTech hub connecting manufacturers, sales reps, hospitals and surgeons. Avesi invests in lower-middle-market healthcare services and technology and now has more than $2.2 billion under management. New Age sits between implant makers and the operating room: more than 85 OEMs, 100-plus independent reps, 200-plus hospitals and surgery centers, and 350-plus spine surgeons. Founder and chief executive Kevin Bly remains in place with the current management team. The check is meant to move product from the plant to the table faster, not to recapitalize a clinic chain. (Link)
  7. GoodVets has acquired WellHaven Pet Health, adding more than 40 veterinary hospitals and taking the combined network from 75 to 116 locations. GoodVets, based in Chicago, has mostly opened hospitals from scratch with local veterinarians. WellHaven already runs more than 40 clinics across seven states, with clusters in the Pacific Northwest and the Midwest. Those sites will move onto GoodVets’ central operating model and, over time, onto the GoodVets name. Existing clinic teams and patient panels stay in place. Terms were not published. (Link)
  8. Prisma Health has agreed to acquire 36 South Carolina urgent care centers, formerly Doctor’s Care, from Novant Health. Novant had been running the former Doctor’s Care sites. Closing is set for November 1, when the clinics convert to the Prisma Health Urgent Care name and about 500 employees come across. Patients keep walk-in, booked and virtual visits — including respiratory tests, X-ray and labs — and gain a referral path into Prisma’s hospitals and specialists. Most locations stay put; a few may fold into a neighboring center, with affected staff offered jobs nearby. Purchase price was not disclosed. (Link)
  9. Forge, the B2B events and media company backed by Apollo Funds (APO), has agreed to acquire Becker’s Healthcare from Pamlico Capital, combining it with Fierce Healthcare and Life Sciences to create a scaled healthcare and life sciences media and events platform. Forge, formed by combining Emerald and Questex after their acquisition by Apollo Funds (APO) in July 2026, has signed a definitive agreement to acquire Chicago-based Becker’s Healthcare from Pamlico Capital. The deal includes Becker’s 16 annual conferences, more than a dozen digital publications and its newsletters, podcasts and executive communities, which reach over 1.5 million healthcare leaders. Combined with Forge’s Fierce Healthcare and Life Sciences, the platform will run more than 35 live events. (Link)
  10. May River Capital has sold Addison, Illinois-based environmental monitoring platform Dickson to Copeland, a portfolio company of Blackstone (BX), expanding Copeland’s cold chain monitoring capabilities for healthcare and life sciences customers. May River Capital has sold Dickson to Copeland, a Blackstone (BX) portfolio company with approximately 18,000 employees across more than 40 countries. May River acquired Dickson in April 2018 and turned the family-owned, single-site business into a global environmental monitoring platform serving customers in more than 50 countries from Illinois, France and Malaysia. During its ownership, May River invested in next-generation sensing and cloud-based monitoring and took private Oceasoft, a publicly traded French monitoring company. Dickson serves regulated life sciences, pharmaceutical, healthcare and medical device customers, advancing Copeland’s cold chain intelligence offering (Link)
  11. Arcventis Health Partners has made a majority growth investment in Chicago-based functional medicine and hormone health provider Aligned Modern Health, with existing investor Harbour Point Capital remaining a meaningful shareholder, to fund national telehealth expansion and the launch of peptide therapy. Arcventis Health Partners, a US healthcare investor with growth equity and growth buyout strategies, has taken a majority stake in Aligned Modern Health, while Harbour Point Capital stays on as a meaningful investor. AMH operates 15 clinics across Chicago, a telehealth practice serving patients in more than 20 states and a team of 100-plus clinicians spanning functional medicine, hormone replacement therapy, chiropractic care and acupuncture. The capital will fund national expansion, broader clinical offerings including newly launched peptide therapy, the digital patient experience and provider hiring. AMH accepts most major insurance, which sets it apart from self-pay and concierge models. No valuation was disclosed. (Link)
  12. 1315 Capital has led a growth capital investment in Richmond, Texas-based medical device developer and manufacturer Velentium Medical, joining existing investor Great Point Partners as a significant shareholder to scale commercial manufacturing of wearable and implantable devices. Philadelphia-based 1315 Capital, which manages over $1 billion, led a growth capital investment in Velentium Medical, a developer and manufacturer of active Class II wearable and Class III implantable medical devices. Great Point Partners, which manages about $1.7 billion, remains a significant shareholder. Velentium operates from a 50,000-square-foot manufacturing facility after expanding from an engineering shop into commercial production. Proceeds go to manufacturing capacity, product development and regulatory infrastructure. 1315 takes minority and majority stakes in commercial-stage healthcare and outsourced medtech companies. (Link)
  13. Newly launched Boston private equity firm Haelan Capital Partners has made its first investment in Boca Raton, Florida-based virtual acute care provider NuView Health, pairing its capital with an in-house team of experienced healthcare operators. Boston-based Haelan Capital Partners launched with an investment in NuView Health, a hybrid onsite and virtual care partner to hospitals and provider groups across ICU, neurology, stroke and infectious disease. Founded by Gregg Osenkowski and Scott Castle, Haelan pursues control buyouts of founder-owned, lower middle market tech-enabled healthcare services businesses. Its Growth Enablement Model places an in-house C-suite of healthcare operators alongside the investment team to build portfolio infrastructure. NuView has about 150 active providers across more than 60 facilities and a 15-year clinical track record, and its doctors have treated over one million US patients. No deal value was announced. (Link) (Link)
  14. 5th Century Partners has completed a strategic investment in ION PT Network, a founder-led physical therapy management company serving the workers’ compensation market, to refine its commercial strategy while preserving its clinician-led model. Chicago-based 5th Century Partners, which invests in lower middle-market healthcare and business services companies, has made a strategic investment in ION PT Network. Founded in 2017 by physical therapist Joseph Noel, ION manages workers’ compensation physical therapy for payers, employers and third-party administrators through independent providers, assigning each referral to a licensed clinical case owner; more than half its staff are licensed therapists. 5CP plans to refine ION’s business and commercial strategy while preserving its clinical model. Noel remains CEO, supported by newly added chief revenue officer Sara Mulick and chief financial officer Alina Schreiber. Terms were not disclosed. (Link)
  15. Ascend Learning has acquired AI-powered healthcare workforce scheduling platform M7 Health, combining it with its StaffGarden and Laudio brands to support clinicians from schooling through day-to-day staffing. Boston-based Ascend Learning, a healthcare and learning technology company, has acquired M7 Health, whose AI platform forecasts staffing demand, balances schedules and recruits to fill gaps for health systems ranging from academic medical centers to rural hospitals. M7 customers have cut administrative burden by more than 60%, premium labor spend by 35% and nurse turnover by 30%. The deal pairs M7 with Ascend’s StaffGarden and Laudio brands, extending a platform that supports more than 60% of nursing schools and 245,000 allied health professionals a year. It follows Ascend’s August acquisition of TAMS, continuing its expansion in healthcare workforce technology. Terms were not disclosed. (Link)
  16. Carisk Partners has acquired onsite occupational healthcare provider FirstCare Onsite to connect injured workers with care from the point of injury through complex recovery in the workers’ compensation market. Tampa-based Carisk Partners, a specialty risk transfer, care coordination and clinical services company in workers’ compensation, has acquired FirstCare Onsite. FirstCare places clinicians at employer worksites and has historically resolved roughly 30% of workplace injuries before they became claims. Carisk will keep FirstCare’s onsite model while routing complex cases into its specialty care, complex care management and behavioral health services. Carisk plans to invest in expanding FirstCare’s onsite programs, particularly among large employers with concentrated workforces. (Link)
  17. MGA Homecare has acquired Care IV Home Health’s private duty nursing division, entering Arkansas as its seventh state and expanding in-home care for medically complex pediatric and adult patients. MGA Homecare has acquired Care IV Home Health’s private duty nursing division, which has served medically complex Arkansas patients for more than three decades, including children and adults who depend on ventilators or tracheostomies. The carve-out let’s Care IV focus exclusively on its Medicare intermittent skilled home health business. MGA is keeping the division’s leadership, headed by Joseph Kennon, and its nursing workforce, and plans to use the unit to reach rural and underserved patients and pursue value-based partnerships with health plans. MGA now has more than 5,500 team members serving over 6,000 patients daily across seven states. Terms were not disclosed. (Link)
  18. Nashville-based Chord Specialty Dental Partners has entered Ohio by partnering with Ohio-based pediatric practices Prairie Kids Dental of West Jefferson and Clover Kids Dental of Columbus, extending its network to eight states. Chord Specialty Dental Partners, a Nashville-based dental support organization, has partnered with two Ohio pediatric practices: Prairie Kids Dental in West Jefferson and Clover Kids Dental in Columbus. Both practices are led by founder Kimberly Gill, DDS. The deal marks Chord’s entry into Ohio and brings its footprint to eight states. Chord supports more than 60 partner practices across pediatric dentistry, orthodontics, oral surgery and ambulatory surgery centers. The deal adds to an active consolidation market: professional services, the segment Healthcare DealHub files it under, leads that site’s 2026 year-to-date healthcare deal count with 386 transactions. Terms were not disclosed. (Link)
  19. Hope Network has acquired Developmental Enhancement Behavioral Health, a roughly 90-person West Michigan autism services provider, nearly doubling the footprint of its Center for Autism. Michigan’s Hope Network has acquired Developmental Enhancement Behavioral Health, a roughly 90-person provider of Applied Behavior Analysis, psychological assessment and counseling with locations in Grand Rapids, Holland and Georgetown Township. The deal nearly doubles the footprint of Hope Network’s Center for Autism, which operates in Kentwood, Holland Township, Livonia and Okemos. Financial terms were not released. Integration is planned in phases through about spring 2027. DE locations, clinicians and care models stay in place, with no immediate rebranding. (Link)
  20. Penn Medicine, Independence Blue Cross (IBX) and Regent Surgical have formed a new joint company to develop at least 18 ambulatory surgery centers across Greater Philadelphia, combining health-system, payer and ASC operator capabilities to shift procedures into lower-cost outpatient settings. Penn Medicine, Independence Blue Cross and Regent Surgical are launching a new company to develop at least 18 ambulatory surgery centers across Pennsylvania, New Jersey and Delaware. Penn brings the clinical network, IBX the payer, and Regent the ASC development and operating platform. Hospital facility fees can run close to twice ASC fees; Vizient has projected outpatient surgical volumes up 20 percent through 2035. No financial terms were disclosed. (Link)
  21. OceanSound Partners-backed PAR Excellence Systems, based in Cincinnati, Ohio, has acquired Madison, Wisconsin-based healthcare RFID inventory tracking company Terso Solutions from Promega Corporation to build a unified hospital inventory management platform. PAR Excellence Systems, an OceanSound Partners portfolio company, has acquired Terso Solutions from its parent, Promega Corporation. Terso makes ultra-high-frequency RFID enclosures, open-air readers and cloud software that let hospitals track high-value inventory in real time, with thousands of enclosures installed across hundreds of hospitals and health systems, including the US Department of Veterans Affairs. The companies have worked together for years, and hundreds of PAR clients already connect Terso enclosures to PAR’s TrackCore tissue and implant tracking software. The combined business serves about 1,700 hospitals, nearly 30% of the roughly 6,000 in the US, and aims to replace fragmented point solutions. Financial terms were not disclosed. (Link)
  22. RS2 Healthcare Partners has completed its first new platform investment since refocusing exclusively on healthcare, backing Hatboro, Pennsylvania-based medical device contract manufacturer KMM Group and appointing J. Mark King as CEO. Boston-based RS2 Healthcare Partners, formerly Riverside Partners, has invested in KMM Group, a vertically integrated precision contract manufacturer of complex, tight-tolerance components for the medical device industry. The deal is RS2’s first new platform since the firm rebranded earlier this year to focus exclusively on lower middle-market healthcare; RS2 has raised $1.6 billion in total commitments since its 1989 founding. RS2 appointed J. Mark King, previously CEO of former RS2 portfolio company Tegra Medical, as KMM’s president and CEO. Founders John Shegda and Eric Wilhelm stay on as chief technology officer and executive vice president of business transformation, respectively. No terms were announced. (Link)
  23. Arlington Capital Partners portfolio company AVS Bio has acquired Cambridge, UK-based bio-reagent supplier Biorbyt Ltd. to expand its biomaterials catalog and ecommerce capabilities. AVS Bio, a Norwich, Connecticut provider of bioprocessing inputs and services backed by Arlington Capital Partners, has acquired Biorbyt Ltd., a Cambridge, UK supplier with more than 1 million SKUs of antibodies, proteins, ELISA kits and molecular biology reagents. The add-on expands AVS Bio’s research catalog and adds Biorbyt’s ecommerce channel. Arlington is investing from its $6 billion Fund VII. Biorbyt’s leadership team stays in place. (Link)
  24. Audax Private Equity-backed Elevate ENT Partners has acquired West Texas Ear, Nose & Throat, expanding its otolaryngology physician practice management platform across Texas. Elevate ENT Partners, backed by Audax Private Equity, has acquired West Texas Ear, Nose & Throat, which operates locations in Abilene and Brownwood. The practice is led by its sole physician, Dr. Jason Acevedo, with 11 healthcare and administrative staff, and provides otolaryngology, head and neck surgery and allergy treatment. The deal is Elevate’s first practice acquisition of 2026 and extends its reach across Texas. Elevate supports a national network of more than 80 otolaryngology centers and over 130 affiliated physicians. It gives physician-led ENT and allergy practices management infrastructure, revenue cycle management, payer contracting, human resources and operational scale. Financial terms were not disclosed. (Link)
  25. Rays of Belief Limited (MOMSBELIEF), operating as Mom’s Belief, has acquired 100% of New York-based pediatric Early Intervention provider City Pro Group through its subsidiary Mom’s Belief US Inc. to build a US developmental care platform. India-based Rays of Belief (MOMSBELIEF), which runs 136 developmental care centres under the Mom’s Belief brand, has acquired all of City Pro Group through wholly owned subsidiary Mom’s Belief US Inc., effective September 18, 2026. Founded in 1995, CPG provides pediatric Early Intervention and special education services across the Bronx, Brooklyn, Manhattan and Long Island. CPG generated US$11.43 million (about ₹97.27 crore) of FY25 revenue, more than the acquirer’s FY26 consolidated revenue of ₹81.66 crore, so the deal could roughly double the group’s scale. The acquisition gives the company a US operating platform and a two-way exchange of clinical know-how between India and the US. Consideration was not disclosed. (Link)

Venture Deals and Other

  1. Pershing Square Inc. (PS), the Ackman Oxman Institute and an undisclosed life sciences investment fund have co-led Precision Neuroscience’s oversubscribed $250 million Series D, joined by Duquesne Family Office, B Capital, ARK Invest, Invus, Mubadala Capital, Mirae Asset Capital, Korea Investment Partners (parent Korea Investment Holdings, KRX: 071050), Hitachi Ventures (parent Hitachi, TYO: 6501) and JSL Health Capital, to advance its brain-computer interface toward commercialization. Pershing Square Inc. (PS), the Ackman Oxman Institute and an undisclosed life sciences fund co-led Precision Neuroscience’s oversubscribed $250 million Series D, lifting total capital raised to $430 million since the brain-computer interface developer was founded in 2021. Duquesne Family Office, B Capital, ARK Invest, Invus, Mubadala Capital, Mirae Asset Capital, Korea Investment Partners (parent KRX: 071050), Hitachi Ventures (parent TYO: 6501) and JSL Health Capital also joined, spanning sovereign wealth, venture, public-market and family-office capital. Precision holds FDA clearance for its Layer 7 cortical interface, has completed more than 100 procedures across 18 institutions and partners with Medtronic (MDT). Proceeds will fund clinical expansion, further FDA review and commercialization. (Link)
  2. Francisco Partners has led a $155 million Series E in pharmacy benefit management and care navigation company Rightway, with participation from existing investors Thrive Capital and Khosla Ventures, to expand its AI and technology capabilities. Francisco Partners led a $155 million Series E in New York-based Rightway, with existing investors Thrive Capital and Khosla Ventures participating. Rightway provides pharmacy benefit management and care navigation for employers. Its financial model removes any incentive to profit from higher drug spend, and pharmacists guide members to the most appropriate medications at the lowest cost. It now counts 45 Fortune 500 companies as clients, nearly 10% of the index. Its SureSpend model caps total pharmacy spend and covers GLP-1s and rare high-cost drugs at net cost with 100% rebate pass-through. Proceeds will expand Rightway’s AI and technology. Francisco Partners, with over $75 billion raised, brings healthcare technology expertise. (Link)
  3. .406 Ventures has led a $22 million Series A in at-home cervical cancer screening company Teal Health, with continued backing from Emerson Collective (managed by Yosemite), Forerunner and Serena Ventures and new participation from Japan-based MPower Partners, ahead of broad insurance coverage in 2027. .406 Ventures led a $22 million Series A in Teal Health, maker of the Teal Wand, the first FDA-authorized self-collection device for at-home HPV cervical cancer screening. Emerson Collective (managed by Yosemite), Forerunner and Serena Ventures returned, and Japan-based MPower Partners joined, lifting total funding to $45 million. Federal guidelines due in January 2027 require most health plans to cover self-collection screening. Proceeds go to payor, health system, employer and provider contracts, direct-purchase channels and hiring. Teal reports that 59 percent of women who use the wand had been underscreened. (Link)
  4. NEA has led a $20 million Series A in Nashville-based AI post-acute admissions platform Basalt Health, with participation from existing investors Frist Cressey Ventures and 25m Health, to scale across Lifepoint Health and ScionHealth hospitals. Return investor NEA led a $20 million Series A in Nashville-based Basalt Health, with existing backers Frist Cressey Ventures and 25m Health, 25madison’s healthtech venture studio, participating; total funding now stands at about $24.5 million. Basalt’s AI reads post-acute referrals and checks them against clinical and payer rules, cutting median processing time by 86% at Lifepoint Health. The capital will support scaling across 111 markets by the end of 2026, including 62 ScionHealth hospitals and 49 Lifepoint markets, plus expansion into discharge and payer workflows. NEA, with more than $38 billion in assets under management, and Frist Cressey, with $846 million, bring deep healthcare networks. (Link)
  5. Accel has led a $10 million seed round in New York-based healthcare conversational AI company Clarion Health, with participation from Y Combinator, to automate scheduling, referrals, prescription refills and patient communications for providers. Accel led a $10 million seed round in New York-based Clarion Health, with participation from Y Combinator. Clarion’s conversational AI platform automates scheduling, referrals, prescription refills and patient communications for healthcare providers. Founded in 2024 by Ryan Gallagher and Jeffrey Lamothe, the company is building what Y Combinator calls an AI communication layer for healthcare, with agents that handle the overwhelming volume of calls and messages providers receive. The Accel-led round gives the two-year-old startup capital to scale its AI communication infrastructure for healthcare providers, and the company is actively hiring following the raise. (Link)
  6. Surgeon investors have backed Redefine Surgery’s oversubscribed pre-seed round, bringing total capital raised to $10 million, as Catalyst OrthoScience joins as Founding Partner to co-develop surgical intelligence for shoulder replacement. Redefine Surgery has closed an oversubscribed pre-seed round backed mostly by surgeon investors, bringing total capital raised to $10 million. The company is combining computer vision, software and robotics in a portable platform for the operating room, starting in orthopedics. Naples, Florida-based Catalyst OrthoScience joined as founding partner on surgical intelligence for shoulder replacement. More than 25 surgeons advise the company. Commercial use still requires regulatory clearance. (Link)
  7. Ground State Ventures has led a $3.4 million pre-seed round in Azulene Labs, with participation from existing investor Entrada Ventures and angel investors, to build physics-based AI models for drug and materials simulation. Ground State Ventures led a $3.4 million pre-seed round in Azulene Labs, with participation from existing investor Entrada Ventures and angel investors. Azulene builds physics-based models trained on quantum-mechanical data for drug and materials simulation. Co-founder Nicolas Sawaya previously led quantum chemistry algorithm work at Intel Labs. Proceeds go to hiring and to work with biotech and industrial chemistry customers. (Link)
  8. Elmstead Partners, Chisos Capital, the Chemical Angel Network and individual angel investors have backed Axio BioPharma’s $2.4 million pre-seed round to connect biomanufacturing data between pharma companies and their manufacturing partners. Elmstead Partners, Chisos Capital, the Chemical Angel Network and a group of individual angels invested in Axio BioPharma’s $2.4 million pre-seed round. The Madison, Wisconsin company connects manufacturing data between drug sponsors and their manufacturing partners through a product called Lattice, with each side keeping its own systems. Proceeds fund first deployments with design partners and further work on Rosetta, an ontology layer that maps those systems to each other. (Link)

CLICK HERE to sign up
for all news and updates